Leerink Partnrs Has Weak Forecast for enGene FY2029 Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Analysts at Leerink Partnrs reduced their FY2029 EPS estimates for shares of enGene in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of $0.57 per share for the year, down from their previous forecast of $0.60. The consensus estimate for enGene’s current full-year earnings is ($1.57) per share.

Several other research analysts also recently weighed in on the stock. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. Raymond James started coverage on shares of enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. HC Wainwright started coverage on shares of enGene in a research note on Monday, December 23rd. They issued a “buy” rating and a $25.00 target price for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of enGene in a research note on Monday, December 23rd. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $29.78.

enGene Trading Up 4.9 %

Shares of ENGN stock opened at $7.29 on Thursday. The firm has a 50-day moving average price of $7.39 and a 200 day moving average price of $7.54. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The company has a market capitalization of $322.36 million, a price-to-earnings ratio of -12.57 and a beta of -0.65. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06.

Institutional Trading of enGene

Institutional investors have recently modified their holdings of the company. Wolverine Asset Management LLC purchased a new stake in shares of enGene during the 3rd quarter worth about $37,000. Point72 Asset Management L.P. grew its holdings in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares during the period. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.